Caliway’s drug molecule CBL-514 to treat Dercum’s disease receives EMA orphan drug designation: New Taipei City Thursday, November 14, 2024, 16:00 Hrs [IST] Caliway Biopharmac ...

Caliway has completed a CBL-514 Phase 2 study (CBL-0201DD, NCT05387733) for Dercum's disease in 2023. The study results demonstrated that after administrating CBL-514 treatment, 64.5% of painful ...

HONOLULU (HawaiiNewsNow) - Hawaii veterans have joined efforts to get records from a classified base updated so those ...

Japanese gynecological benign tumor market is thriving with cutting-edge diagnostic technologies and minimally invasive ...